药物经济学研究助力创新药医保准入风险共担机制建立  

Pharmacoeconomic researches facilitate innovative drug access in medical insurnace list through establishing risk-sharing agreement

作　　者：邓诗姣 胡敏[1,2] 解君 王欣 DENG Shi-jiao;HU Min;XIE Jun;WANG Xin(School of Public Health,Fudan University,Shanghai 200032,China;Center for Research and Evaluation in Pharmacoeconomics,Fudan University,Shanghai 200032,China)

机构地区：[1]复旦大学公共卫生学院,上海200032 [2]复旦大学药物经济学研究与评估中心,上海200032

出　　处：《世界临床药物》2020年第12期917-920,共4页World Clinical Drug

基　　金：国家社科基金重大项目(20ZDA072)。

摘　　要：创新药医保准入面临财务及疗效风险。风险共担机制包括财务成本分摊的风险共担协议和基础于治疗结果的风险共担协议,通过在医保购买方与制药企业间建立协议,两者共同分担上述风险,使医保承担的风险控制在可接受范围内。药物经济学研究可以定量测量药品的可负担性和经济性,是设计风险共担机制的覆盖范围和支付标准的有力工具,可帮助有效建立创新药风险共担机制,优化创新药的准入问题。The medical insurance access of innovative drugs brings high-level financial or outcome risks to the payers.The risk-sharing agreements,including cost-sharing arrangements and outcome-based risk-sharing arrangements,can make the payers and manufacturers share the future risks,relieving the burdens of the payers.Pharmacoeconomic researches which can quantitatively measure affordability and cost-effectiveness of the drugs,are regarded as a powerful tool for designing coverage and payment standards of risk sharing schemes and thus facilitating the patient access of innovative drugs.

关 键 词：药物经济学研究 创新药 医保准入 风险共担机制 

分 类 号：R19[医药卫生—卫生事业管理]